Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Drugs and Therapy
Erschienen in: Cardiovascular Drugs and Therapy 6/2022

07.09.2021 | Original Article

HPMC improves protective effects of naringenin and isonicotinamide co-crystals against abdominal aortic aneurysm

verfasst von: Xing Zhang, Anyi Wang, Xiaotong Yang, Yunxia Wang, Qinyu Wang, Rui Hu, Gulinigaer Anwaier, Chang Di, Rong Qi, Yanbin Huang

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Abdominal aortic aneurysm (AAA) rupture is one of the most common causes of mortality in cardiovascular diseases, but currently there is no approved drug for AAA treatment or prevention in the clinic. Naringenin (NGN) has been reported to have anti-AAA effects. However, water solubility and in vivo absorption of NGN are not satisfactory, which leads to its low bioavailability, thus affecting its pharmacological effects. In this project, the improving effects of isonicotinamide (INT) co-crystal and hydroxy propyl methyl cellulose (HPMC) or polyvinyl pyrrolidone (PVP) on the solubility, in vivo absorption, and anti-AAA effects of NGN were evaluated.

Methods

In the current study, co-crystals of naringenin-isonicotinamide (NGN-INT) were prepared, and effects of PVP or HPMC on precipitation rate, supersaturation, and bioavailability of NGN were explored. In addition, with or without HPMC supply, the effects of NGN-INT co-crystal on anti-AAA efficacy of NGN were investigated on an elastase-induced AAA mouse model, and the results were compared with the efficacy of the NGN crude drug.

Results

Our results demonstrate that NGN-INT formulation, compared to the NGN crude drug, enhanced the dissolution rate of NGN and significantly increased Cmax and AUC(0–∞) of NGN by 18 times and 1.97 times, respectively. Addition of PVP or HPMC in NGN-INT co-crystal further increased bioavailability of NGN in NGN-INT. The in vivo pharmacodynamic study showed that NGN-INT with HPMC significantly improved the inhibitory effects of NGN against AAA.

Conclusion

NGN-INT significantly improved the absorption and aortic protective effects of NGN. The supersaturation-prolonging effect of HPMC further enhanced bioavailability and anti-AAA effects of NGN-INT.

Graphical abstract

Literatur
1.
Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med. 1997;126(6):441–9.CrossRefPubMed
2.
Alcorn HG, Wolfson SK, Sutton-Tyrrell K, Kuller LH, Oleary D. Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1996;16(8):963–70.CrossRefPubMed
3.
Tang L, Cong Z, Hao S, Li P, Huang H, Shen Y, et al. Protective effect of melatonin on the development of abdominal aortic aneurysm in a rat model. J Surg Res. 2017;209:266.CrossRefPubMed
4.
Htun NM, Peter K. Biomarkers for AAA: Encouraging steps but clinical relevance still to be delivered. Proteom Clin Appl. 2015;8(9-10):732–4.CrossRef
5.
Gillum RF. Epidemiology of aortic aneurysm in the United States. J Clin Epidemiol. 1995;48(11):1289–98.CrossRefPubMed
6.
Best VA, Price JF, Fowkes FGR. Persistent increase in the incidence of abdominal aortic aneurysm in Scotland, 1981-2000. Br J Surg. 2010;90(12):1510–5.CrossRef
7.
Liu Y. Study on the preparation method of naringenin. Chin J Spectr Lab. 2008;25(6):1292–4.
8.
Chen XF, Liu D, Li X. Study on supercritical CO2 extraction rocess of nagringenin from peach leaf. Food Sci. 2007;28(1):106–9.
9.
Liu WY, Huo P, Mei GQ, Xiong ZX, Wang RJ. The study on microwave synthesis and antibacterial activity of Hhesperetin aromatic hydrazone compounds. J Jiangxi Norm Univ. 2012;36(2):193–5.
10.
Chen Y, Nie YC, Luo YL, Lin F, Zheng YF, Cheng GH, et al. Protective effects of naringin against paraquat-induced acute lung injury and pulmonary fibrosis in mice. Food Chem Toxicol. 2013;58(4):133–40.CrossRefPubMed
11.
Kong W, Cui Q, Liu Z, Yu F, inventors; Use of naringenin in preparing drugs for preventing and/or treating abdominal aortic aneurysm. China patent WO 2014/206056 A1. 2014.12.31.
12.
Liang S, Zhou S, Yang S, Xia D, Wei Y, Gao Y, et al. Thermodynamic studies of naringenin-isonicotinamide cocrystals. Acta Pharm Sin. 2017;04:625–33.
13.
Cui WX, He ZH, Zhang YT, Fan QY, Feng NP. Naringenin cocrystals prepared by solution crystallization method for improving bioavailability and anti-hyperlipidemia effects. AAPS PharmSciTech. 2019;20(3):1–12.CrossRef
14.
Toth B. Lack of carcinogenicity of nicotinamide and isonicotinamide following lifelong administration to mice. Oncology. 1983;40(1):72–5.CrossRefPubMed
15.
Fukaya M, Tamura Y, Chiba Y, Tanioka T, Kaneki MJB. Protective effects of a nicotinamide derivative, isonicotinamide, against streptozotocin-induced β-cell damage and diabetes in mice. Biochem Biophys Res Commun. 2013;442(1–2).
16.
Rowe R, Sheskey P, Quinn M. Handbook of Pharmaceutical Excipients. 6th ed. London: Pharmaceutical Press; 2009.
17.
Zhang J, Xia D, Xu J, Gao Y, inventors; Naringenin isonicotinic acid eutectic. China patent CN 104817526 A. 2015.08.05.
18.
Sun DD, Wen H, Taylor LS. Non-sink dissolution conditions for predicting product quality and in vivo performance of supersaturating drug delivery systems. J Pharm Sci. 2016;105(9):2477–88.CrossRefPubMed
19.
Wang Y, Chen C, Wang Q, Cao Y, Xu L, Qi R. Inhibitory effects of cycloastragenol on abdominal aortic aneurysm and its related mechanisms. Br J Pharmacol. 2019;176(2):282–96.CrossRefPubMed
20.
Chen C, Jie X, Ou Y, Cao Y, Xu L, Wang Y, et al. Nanoliposome improves inhibitory effects of naringenin on nonalcoholic fatty liver disease in mice. Nanomedicine. 2017;12(15):1791–800.CrossRefPubMed
21.
Khan AW, Kotta S, Ansari SH, Sharma RK, Ali J. Enhanced dissolution and bioavailability of grapefruit flavonoid Naringenin by solid dispersion utilizing fourth generation carrier. Drug Dev Ind Pharm. 2015;41(5):772.CrossRefPubMed
22.
Ziller KH, Rupprecht H. Control of crystal growth in drug suspensions. Drug Dev Ind Pharm. 1988;14:2341–70.CrossRef
23.
Yang X, Shen B, Huang Y. Mechanistic study of HPMC-prolonged supersaturation of hydrocortisone. Cryst Growth Des. 2015;15(2):546–51.CrossRef
24.
Babu JN, Nangia A. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst Growth Des. 2011;11(7):2662–79.CrossRef
25.
Kuminek G, Cao F, Rocha ABDOD, Cardoso SG, Rodríguez-Hornedo N. Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5. Adv Drug Deliv Rev. 2016;101:143–66.CrossRefPubMedPubMedCentral
26.
Jasani MS, Kale DP, Singh IP, Bansal AK. Influence of drug-polymer interactions on dissolution of thermodynamically highly unstable cocrystal. Mol Pharm. 2019;16(1):151–64.CrossRefPubMed
27.
28.
Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013;65(1):315–499.CrossRefPubMed
29.
Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007;96:2686–702.CrossRefPubMed
30.
Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability. J Pharm Sci. 2009;98:2549–72.CrossRefPubMed
31.
Gao P, Morozowich W. Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs. Expert Opin Drug Del. 2006;3:97–110.CrossRef
32.
Bao L, Zhu J, Li Z. Effect of intraperitoneal fluid replacement on diarrhea in piglets. Agr Equip Tech. 2012;5:35–6.
Metadaten
Titel
HPMC improves protective effects of naringenin and isonicotinamide co-crystals against abdominal aortic aneurysm
verfasst von
Xing Zhang
Anyi Wang
Xiaotong Yang
Yunxia Wang
Qinyu Wang
Rui Hu
Gulinigaer Anwaier
Chang Di
Rong Qi
Yanbin Huang
Publikationsdatum
07.09.2021
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 6/2022
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-021-07206-x

Weitere Artikel der Ausgabe 6/2022

Cardiovascular Drugs and Therapy 6/2022 Zur Ausgabe

Original Article

K-80003 Inhibition of Macrophage Apoptosis and Necrotic Core Development in Atherosclerotic Vulnerable Plaques

Original Article

Schützen Statine vor schwerer COVID-19?

Letter to the Editor

The application of proton pump inhibitors in cardiovascular disease needs to be individualized

Original Article

Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure

Letter to the Editor

Reassessment of Confidence in a Network Meta-analysis of Antidysrhythmic Drugs for Atrial Fibrillation Cardioversion

Invited Review Article

Challenges in Optimizing Lipid Management in Women

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise